Mandarin Capital Dedicated to Alternative Investments in Real Assets. With deep on-the-ground insight and the mindset to accommodate global wisdom, Mandarin Capital develops sophisticated deal and capital structures, and sets up industry-leading platforms to deliver an ongoing deal pipeline and excellent operations.
- Established by the ex-key members of Blackstone's Real Estate China Team.
- Led or closely involved in more than a dozen complicated transactions, collectively worth RMB20 billion GAV.
- Superior institutional-quality operation platforms in the specific sectors ensure a market-leading ability to develop and operate.
Mandarin Capital Focus
Opportunities related to Structural Trends driven by the innovation in technology and business models, as well as Special Situations brought about by emerging cyclical mismatches between policies, industries, and financial environment.
Data Center
In China’s 1st Tier Cities and surrounding areas, providing opportunities to acquire and/or develop institutional quality IDCs with the full regulatory compliance, and invest in the IDC platforms in the private or public markets.
Life Science Infrastructure
In the city areas with proven industry concentrations such as Shanghai, Beijing, Suzhou and Guangzhou.., Acquire and/or develop industry parks and/or single properties that can meet the requirements for scientific R&D and biomanufacturing, and invest in the Life Science Infrastructure platforms in the private or public markets.
Special Situations
Calculate the risk precisely, formulate the correct plan to nimbly achieve win-win outcomes with the distressed seller.
Deep dive with financial organizations to assess their non-performing loans and/or underlying assets.
Identify and develop opportunities within a wide range of proactive management initiatives such as; repositioning, formulation, enhancement, tenanting, cost/expense optimization, etc, in order to grow the Net Operation Income.
Jiang Hua
Managing Partner
Before establishing Mandarin Capital in 2016, Jiang Hua was formerly working with Blackstone, the largest private equity platform in the world, in its Singapore and Hong Kong offices. During this time, he experienced and contributed to an important growth stage of its real estate business in Asia. Jiang Hua participated in the Investment Committee for Blackstone’s first USD5 billion Asia Fund. Jiang Hua led or was closely involved in deploying more than USD500 million of equity into some landmark PERE transactions with partners such as CR Land, SCPG, China Jinmao, etc.
After graduating from Tsinghua University’s School of Economics and Management in 2001,majoring in International Finance, Jiang Hua also earned his MBA from MIT’s Sloan Business School in 2008.
Jiang Hua served as the Executive Director for Everwell Life Science Development Co., Ltd., Haoyang Cloud Data Co., Ltd. and Canadian CT Group, and was Non-Executive Director for the BONA Film Group.
Steven Ma
Managing Director
Before joining Mandarin Capital in 2021, Steven worked with Hines, one of the largest real estate development, investment, and management firms in the world, for more than 10 years, in two tenures. Steven was a Managing Director in charge of business generation, development and management and was involved in the full cycle of fundraising, investment, management and exit on some prestigious projects such as Four Seasons Hotel Pudong, One Museum Place, and Park Avenue. In between, Steven also worked with Blackstone in its Hong Kong and Shanghai offices and led the asset management efforts in mainland China, covering a wide variety of asset classes and strategies, such as warehouse, residential, retail and office.
Steven graduated from the Department of Civil Engineering at Tsinghua University in 2002, majoring in Construction Management Steven also earned a Masters Degree in Construction Management at Tsinghua University in 2004 and a Masters Degree in Management Science and Engineering at Stanford University in 2006.
Steven served as the Executive Director for Everwell Life Science Development Co., Ltd.